An investigation on behalf of current long term investors in Natus Medical Inc (NASDAQ:BABY) shares over possible breaches of fiduciary duty by certain officers and directors was announced and NASDAQ:BABY stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 08/09/2017 -- An investigation on behalf of long-term investors in shares of Natus Medical Inc (NASDAQ:BABY) concerning potential breaches of fiduciary duties by certain directors and officers of Natus Medical Inc was announced.
Investors who are current long term investors in Natus Medical Inc (NASDAQ:BABY) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm for current long term investors in NASDAQ:BABY stocks follows a lawsuit filed recently against Natus Medical Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ:BABY stocks, concerns whether certain Natus Medicaldirectors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that the defendants violated Federal Securities Laws. The plaintiff claims that between October 16, 2015 and April 3, 2016, the defendants issued false and misleading statements and/or failed to disclose adverse information regarding the Company's business and prospects, including, among other things, that the Venezuelan government had failed to make tens of millions of dollars in prepayments to Natus Medical Inc, which were required to have been paid beginning in October 2015, that Natus Medical Inc had no means to effectively enforce its rights under the Supply Contract, as Venezuela was the exclusive forum for dispute resolution, that Natus Medical Inc's receipt of revenues pursuant to the Supply Contract was contingent on the outcome of Venezuelan elections, and that as a result of the foregoing, Natus was not on track to achieve the increased guidance provided by defendants and such guidance lacked a reasonable basis.
Those who purchased shares of Natus Medical Inc have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com